Product Launch Delays
Can lead to deterioration in earnings.
- Materiality
- high
EQL Pharma
EQL Pharma is a pharmaceutical company focused on developing and selling generic prescription drugs and medical tests. The company operates primarily in the Nordic region and has recently expanded its market presence to include parts of Europe and the Gulf Cooperation Council (GCC) countries. EQL Pharma is known for its aggressive growth strategy, which includes launching new products and entering new markets. The company aims to achieve significant sales growth through both organic expansion and strategic acquisitions.
55
2.84
1.03
| % | |
|---|---|
| Generic Prescription Drugs | 70% Includes interchangeable generics for outpatient and hospital care. |
| Medical Tests | 10% Tests for identifying Covid and influenza infections. |
| Distribution Agreements | 10% Includes products distributed in GCC countries. |
| Hospital Products | 5% Injection products for inpatient care. |
| Unique Formulations | 5% Specialized products for outpatient care. |
EQL Pharma serves a diverse range of customer segments primarily in the healthcare sector...
- Pharmaciesprimary
Purchase generic drugs for retail distribution.
- Hospitalssecondary
Acquire injection products for inpatient care.
- International Distributorsemerging
Distribute products in GCC countries.
- Healthcare Providerssecondary
Use unique formulations for specific treatments.
EQL Pharma operates primarily in the Nordic region, with direct sales in Sweden, Denmark, Norway, and Finland...
- •Direct operations in Sweden, Denmark, Norway, and Finland
- •Expanded presence in Estonia, Latvia, Lithuania, Czech Republic, Austria, and Portugal
- •Distribution agreement in GCC countries for market expansion
- •Indirect sales through partners in non-European markets
- •Geographic diversification reduces market-specific risks
EQL Pharma's strategic priorities focus on aggressive growth through product launches and market expansion...
01
Product Launchesshort-term
To drive sales growth and market presence.
02
Market Expansionmedium-term
To increase geographic reach and customer base.
03
Strategic Acquisitionsmedium-term
To enhance product offerings and competitive position.
04
Margin Stabilitylong-term
To ensure financial health and investor confidence.
EQL Pharma faces several business and financial risks, including delays in product launches and increased competition,...
Increased Competition
Could lead to slower sales and weaker profitability.
- Materiality
- high
Capital Requirements
Aggressive growth strategy may need additional funding.
- Materiality
- medium
Transport Disruptions
Affects supply chains and gross margins.
- Materiality
- medium
Revenue Recognition
high
Fair Value Calculations
medium
Acquisition Accounting
high
AQ Group
AQ.ST · Industrials
AQ Group is a global manufacturer specializing in components and systems, with a strong focus on transformers and inductors.
Equillium, Inc.
EQ · Pharmaceutical Preparations
Terveystalo Oyj
TTALO.HE · Medical Care Facilities
Terveystalo is a Finnish healthcare service provider that operates through three main segments: Healthcare Services, Portfolio Businesses, and operations in Sweden.
QuidelOrtho Corp
QDEL · In Vitro & In Vivo Diagnostic Substances
QuidelOrtho Corp develops and markets diagnostic testing products used to detect, monitor, and help manage disease across clinical and decentralized care settings.
Pihlajalinna Oyj
PIHLIS.HE · Medical Care Facilities
Pihlajalinna is a Finnish healthcare company that focuses on providing innovative healthcare pathways and fostering an attractive corporate culture within the industry.
Merck & Co., Inc.
MRK · Pharmaceutical Preparations
: 11/08/2026